Accueil>>Signaling Pathways>> Neuroscience>> Dopamine Receptor>>Perospirone

Perospirone

Catalog No.GC39237

La perospirone (base libre SM-9018) est un antagoniste actif par voie orale du récepteur 5-HT2A (Ki = 0,6 nM) et du récepteur de la dopamine D2 (Ki = 1,4 nM), ainsi qu'un agoniste partiel du récepteur 5-HT1A (Ki = 2,9 nM ).

Products are for research use only. Not for human use. We do not sell to patients.

Perospirone Chemical Structure

Cas No.: 150915-41-6

Taille Prix Stock Qté
200mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire
5mg
65,00 $US
En stock
10mg
111,00 $US
En stock
50mg
389,00 $US
En stock
100mg
667,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Perospirone (SM-9018 free base) is an orally active antagonist of 5-HT2A receptor (Ki=0.6 nM) and dopamine D2 receptor (Ki=1.4 nM), and also a partial agonist of 5-HT1A receptor (Ki=2.9 nM). Perospirone is an atypical antipsychotic drug and has the potential for schizophrenic disease[1][2].

[1]. Kato T, et al. Binding profile of SM-9018, a novel antipsychotic candidate. pn J Pharmacol. 1990 Dec;54(4):478-81. [2]. Hagiwara H, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol. 2008 Jun;18(6):448-54.

Avis

Review for Perospirone

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Perospirone

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.